11 results about "Streptozotocin" patented technology

The invention discloses an application of isoquercitrin in preparation of a medicine for improving insulin resistance and diabetes-related liver diseases, and belongs to the technical field of medicines. According to the application, a high-glucose and high-fat diet and streptozotocin combined method is adopted to successfully construct a type 2 diabetes mouse model; experiments find that the isoquercitrin can effectively relieve the symptoms of weight loss and water intake increase of T2DM mice, significantly reduce the fasting blood-glucose level and improve abnormal glucose tolerance; the isoquercitrin can reduce the liver index of a T2DM mouse, relieve fatty degeneration of the liver and repair a liver cell structure; by activating a PI3K / AKT signal channel, the isoquercitrin up-regulates the expression levels of PI3K, p-AKT, p-GSK3 and GLUT4 and down-regulates the expressions of GSK3 and PEPCK at the same time, so that the insulin resistance of T2DM mice is effectively improved, the fatty degeneration of the liver is improved, and the isoquercitrin has a protection or repair effect on liver injury.

The invention discloses a medicine for treating diabetic retinopathy and application of scorpion venom heat-resistant synthetic peptide in treating the disease, belongs to the field of research and development of polypeptide medicines, and is used for treating or preventing the diabetic retinopathy (DR). Experimental results show that the scorpion venom heat-resistant synthetic peptide (SVHRSP) has the effect of preventing and treating diabetic retinopathy (DR) on a streptozotocin (STZ)-induced mouse experimental diabetes model, and can repress retinal function impairment caused by impairment of streptozotocin (STZ)-induced diabetic mouse retinal photoreceptor cells and retinal nerve inner layer cells; and retina structure damage caused by thinning of the retina thickness of a diabetic mouse induced by STZ (streptozotocin) is inhibited.

The invention discloses application of an HSPA13 gene in preparation of a product for improving diabetic cardiomyopathy, and belongs to the technical field of gene engineering. Aiming at the technical problems of myocardial microvascular endothelial cell glycolysis damage, perfusion insufficiency and cardiac dysfunction caused by long-term hyperglycemia, the invention firstly proves that in a streptozotocin-induced type 1 diabetes mouse model, the expression of HSPA13 in myocardial microvascular endothelial cells is remarkably reduced, and then an endothelium-targeted adeno-associated virus vector AAV-HSPA13 is constructed; and intravenous administration is carried out. Experimental results show that the vector can recover the endothelial glycolysis level, improve coronary flow reserve and significantly relieve the pathological change of DCM. The HSPA13 gene is taken as a core target, can be used for preparing or screening a pharmaceutical composition or a function evaluation model for treating DCM, and has outstanding innovativeness and clinical application prospect.

The invention belongs to the technical field of biological medicines, and particularly relates to application of EPA (eicosapentaenoic acid) plasmalogen in preparation of medicines for improving or preventing diabetic nephropathy, which is characterized by treating diabetic nephropathy mouse models induced by high fat diet and streptozotocin and having insulin resistance and hyperglycemia accompanied by kidney lipid accumulation and glomerular filtration rate reduction, and particularly relates to application of EPA plasmalogen in preparation of medicines for improving or preventing diabetic nephropathy. The treatment effect of the EPA plasmalogen on the diabetic nephropathy is observed; results show that the EPA plasmalogen has obvious effects of improving kidney functions and kidney ectopic lipid deposition on diabetic nephropathy mice induced by high fat diet and streptozotocin, and also has the effects of reducing blood sugar, improving blood fat, reducing insulin resistance and the like. The EPA plasmalogen is used for intervening the diabetic nephropathy for the first time, and an important basis is provided for clinically treating the diabetic nephropathy by using the EPA plasmalogen.

This invention belongs to the field of biomaterials technology, specifically relating to a bioactive scaffold, its preparation method, and its applications. This invention incorporates functionalized mesoporous silica nanoparticles loaded with aminoguanidine into the skin secretions of the giant salamander and polycaprolactone electrospun fibers to construct a bioactive composite scaffold (SPMA). This scaffold enables the sustained release of AG and osteogenic factors, effectively inhibiting free radical generation, AGEs toxicity, and inflammatory responses. Furthermore, it significantly improves the survival rate, osteogenic differentiation, and mineralization capacity of bone marrow mesenchymal stem cells in a high-glucose microenvironment. In vivo experiments further demonstrate that in a streptozotocin-induced diabetic mouse model of skull defects, the SPMA scaffold can alleviate local inflammation, promote angiogenesis, and significantly accelerate new bone formation and defect repair.

This invention discloses the application of a traditional Chinese medicine composition in the preparation of a drug for treating sarcopenia, wherein the traditional Chinese medicine composition consists of Astragalus membranaceus and Anemarrhena asphodeloides. The study found that the combination of Astragalus membranaceus and Anemarrhena asphodeloides can significantly improve the differentiation function of C2C12 myoblasts induced by high glucose and inhibit lipid deposition, and improve skeletal muscle mass, muscle strength, and motor function in a streptozotocin-induced C57BL / 6 diabetic sarcopenia mouse model. In vitro and in vivo experiments have confirmed that this drug has significant effects in improving muscle atrophy, enhancing motor function, and restoring muscle strength; it can effectively increase the cross-sectional area of ​​muscle fibers, promote myotube fusion, and accelerate damage repair, showing a clear potential to inhibit diabetic muscle atrophy. This provides an effective traditional Chinese medicine compound intervention strategy for the clinical treatment of diabetic sarcopenia and has good prospects for development and application.

The invention discloses an equivalent component group of Gegen Qinlian decoction for improving type 2 diabetes mellitus and application of the equivalent component group. The invention provides an equivalent component group for treating type 2 diabetes mellitus by using a Gegen Qinlian decoction. The equivalent component group consists of 13, 19 or 27 chemical components. A zebra fish diabetes model and a high fat diet combined streptozotocin induced type 2 diabetes mouse model prove that the equivalent component group consisting of 13, 19 or 27 chemical components has an obvious treatment effect on type 2 diabetes, the treatment effect is not remarkably different from that of the original formula of the Gegen Qinlian decoction, and the excellent equivalence is shown. Therefore, the composition provided by the invention can be used as an equivalent component group of the Gegen Qinlian decoction for treating the type 2 diabetes mellitus, and is further used for preparing a medicine for equivalently replacing the Gegen Qinlian decoction for improving the type 2 diabetes mellitus, or is used for preparing a composition for controlling the quality of the Gegen Qinlian decoction.

The invention relates to the technical field of biomedical experimental animal models, in particular to a drug induction-based miniature pig diabetes mellitus model construction method and application. The drug-induced miniature pig diabetes model construction method comprises the following steps: mixing a citric acid solution with a sodium citrate solution to obtain a mixed solution, and adjusting the pH value of the mixed solution to 4.2-5.0 to obtain a citric acid buffer solution; under the dark condition, streptozotocin is dissolved in the citric acid buffer solution, and a streptozotocin solution is obtained; the prepared streptozotocin solution is injected into the ear edge vein of the fasting miniature pig at a time, and construction of the miniature pig diabetes mellitus model is completed; the injection dosage in the step S3 is 140 to 160 mg / kg. The construction steps of the miniature pig diabetes model are simplified, the long-term stable miniature pig diabetes model can be constructed, and a simpler, more convenient and more stable model construction method is provided for research on a miniature pig diabetes disease mechanism and a treatment method.

The invention belongs to the technical field of animal biology, and particularly relates to a pancreatic cancer related diabetes mouse model construction method, which comprises: preparing a pancreatic cancer cell suspension; preparing a streptozotocin solution; injecting the pancreatic cancer cell suspension to the pancreatic head of the pancreas of the mouse, and establishing a pancreatic cancer model; and 3-5 days after injection is completed, continuously carrying out intraperitoneal injection on the mouse by utilizing a streptozotocin solution once a day, and continuously carrying out injection for 3-5 days, so as to obtain the pancreatic cancer related diabetes mouse model. The animal model of pancreatic cancer related diabetes mellitus is successfully constructed through pancreatic cancer orthotopic transplantation tumor and intraperitoneal injection of STZ, and the model shows wide application potential in the fields of basic and clinical research.

The invention provides application of a compound shown in a formula (I) in preparation of a medicine for improving male reproductive capacity. According to the application, a nano micro-plastic and plasticizer induced Kunming mouse environment pollution type oligospermia and asthenospermia model, a streptozotocin induced Kunming mouse diabetes type oligospermia and asthenospermia model and a sodium valproate induced Kunming mouse anti-epileptic drug type oligospermia and asthenospermia model are respectively constructed; the improvement effect of the compound shown in the formula (I) on male reproductive capacity damage is verified through sperm counting analysis, sperm motility analysis, inflammation and antioxidant gene mRNA expression level analysis, testis tissue pathological damage analysis and the like, and experimental results show that the compound shown in the formula (I) increases the sperm number of mice suffering from oligospermia and asthenospermia, and has a good application prospect. According to the application, the sperm motility of mice with oligospermia and asthenozoospermia is improved, the tissue pathological damage of the testis is improved, the expression of inflammatory factors is inhibited, the expression of antioxidant genes is increased, and the application has great potential in the aspect of treating oligospermia and asthenozoospermia.

The invention discloses an application of malic acid in preparation of a medicine for improving insulin resistance and diabetes-related liver diseases, and belongs to the technical field of medicines. According to the application, a high-glucose and high-fat diet and streptozotocin combined method is adopted to successfully construct a type 2 diabetes mouse model; experiments find that malic acid can effectively relieve the symptoms of weight loss and water intake increase of T2DM mice, significantly reduce the fasting blood-glucose level and improve abnormal glucose tolerance; malic acid can reduce the liver index of a T2DM mouse, relieve fatty degeneration of the liver and repair a liver cell structure; the malic acid is used for activating a PI3K / AKT signal channel to up-regulate the expression levels of PI3K, p-AKT, p-GSK3 and GLUT4 and down-regulate the expression of GSK3 and PEPCK at the same time, so that the insulin resistance of T2DM mice is effectively improved, the fatty degeneration of the liver is improved, and the malic acid has a protection or repair effect on liver injury.